Lejon V, Lindner AK, Franco JR. Human African trypanosomiasis. Lancet. 2025;405(10482):937–50.

Article  PubMed  Google Scholar 

World Health Organization. Guidelines for the treatment of human African trypanosomiasis. 2024. https://iris.who.int/server/api/core/bitstreams/4da65589-ada0-40de-837c-1033af9733c4/content. Accessed 16 Jun 2026.

Franco JR, Cecchi G, Paone M, et al. The elimination of human African trypanosomiasis: achievements in relation to WHO road map targets for 2020. PLoS Negl Trop Dis. 2022;16(1):e0010047.

Article  PubMed  PubMed Central  Google Scholar 

Sanofi Winthrop Industrie. Acoziborole Winthrop: EU prescribing information. 2026. https://www.ema.europa.eu/en/documents/outside-eu-product-information/acoziborole-winthrop-product-information_en.pdf. Accessed 16 Jun 2026.

European Medicines Agency Committee for Medicinal Products for Human Use. CHMP summary of positive opinion for Acoziborole Winthrop. 2026. https://www.ema.europa.eu/en/documents/outside-eu-smop-initial/chmp-summary-positive-opinion-acoziborole-winthrop_en.pdf. Accessed 16 Jun 2026.

European Medicines Agency. New single-dose oral treatment for human African trypanosomiasis (sleeping sickness) [media release]. 27 Feb 2026. https://www.ema.europa.eu/en/news/new-single-dose-oral-treatment-human-african-trypanosomiasis-sleeping-sickness.

Sanofi. Acoziborole Winthrop, developed by DNDi and Sanofi, receives CHMP positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness [media release]. 27 Feb 2026. https://www.sanofi.com/en/media-room/press-releases/2026/2026-02-27-10-55-51-3246379.

Pfizer. Pfizer completes acquisition of Anacor [media release]. 24 Jun 2016. https://www.pfizer.com/news/press-release/press-release-detail/pfizer_completes_acquisition_of_anacor.

DNDi. TB Alliance and DNDi announce collaborations with Anacor to apply boron technology to identify new medicines for neglected diseases [media release]. 27 May 2009. https://dndi.org/press-releases/2009/tb-alliance-and-dndi-announce-collaborations-with-anacor-to-apply-boron-technology-to-identify-new-medicines-for-neglected-diseases/.

DNDi. DNDi research and development portfolio: sleeping sickness: acoziborole. 2026. https://dndi.org/research-development/portfolio/acoziborole/. Accessed 16 Jun 2026.

DNDi. Innovative partnership advances novel drug candidate to combat sleeping sickness [media release]. 28 Jun 2011. https://dndi.org/press-releases/2011/oxaborolesbio/.

DNDi. Innovative single-dose oral sleeping sickness treatment to be co-developed by Sanofi and DNDi partnership [media release]. 4 Sep 2020. https://dndi.org/press-releases/2020/innovative-single-dose-oral-sleeping-sickness-treatment-to-be-co-developed-by-sanofi-and-dndi/.

Sanofi. Acoziborole: investigational single-dose oral treatment raises hope for elimination of sleeping sickness in Africa [media release]. 30 Nov 2022. https://www.sanofi.com/en/media-room/press-releases/2022/2022-11-30-07-00-00-2564640.

Anacor Pharmaceuticals LLC. Boron containing small molecules as antiprotozoal agents [patent number US9449994]. 2010.

Waithaka A, Clayton C. Clinically relevant benzoxaboroles inhibit mRNA processing in Trypanosoma brucei. BMC Res Notes. 2022;15(1):371.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Wall RJ, Rico E, Lukac I, et al. Clinical and veterinary trypanocidal benzoxaboroles target CPSF3. Proc Natl Acad Sci U S A. 2018;115(38):9616–21.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Sharma A, Cipriano M, Ferrins L, et al. Hypothesis-generating proteome perturbation to identify NEU-4438 and acoziborole modes of action in the African trypanosome. iScience. 2022;25(11):105302.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Jacobs RT, Nare B, Wring SA, et al. SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasis. PLoS Negl Trop Dis. 2011;5(6):e1151.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Wring S, Gaukel E, Nare B, et al. Pharmacokinetics and pharmacodynamics utilizing unbound target tissue exposure as part of a disposition-based rationale for lead optimization of benzoxaboroles in the treatment of stage 2 human African trypanosomiasis. Parasitology. 2014;141(1):104–18.

Article  PubMed  CAS  Google Scholar 

Kumeso VKB, Kalonji WM, Rembry S, et al. Efficacy and safety of acoziborole in patients with human African trypanosomiasis caused by Trypanosoma brucei gambiense: a multicentre, open-label, single-arm, phase 2/3 trial. Lancet Infect Dis. 2023;23(4):463–70.

Article  Google Scholar 

Tarral A, Hovsepian L, Duvauchelle T, et al. Determination of the optimal single dose treatment for acoziborole, a novel drug for the treatment of human African trypanosomiasis: first-in-human study. Clin Pharmacokinet. 2023;62(3):481–91.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Gillon J-Y, Simon F, Sidhu S, et al. Mass balance, pharmacokinetics, metabolism, and excretion of radiolabeled acoziborole, a potential novel treatment for human African trypanosomiasis, following single microtracer oral dose to humans. Antimicrob Agents Chemother. 2025;69(11):e0058025.

Article  PubMed  PubMed Central  Google Scholar 

European Medicines Agency Committee for Medicinal Products for Human Use. Acoziborole Winthrop: public assessment report. 2026. https://www.ema.europa.eu/en/documents/outside-eu-assessment-report/acoziborole-winthrop-public-assessment-report_en.pdf. Accessed 16 Jun 2026.

US National Institutes of Health. ClinicalTrials.gov identifier: NCT05256017. 2022. https://clinicaltrials.gov/study/NCT05256017. Accessed 16 Jun 2026.

US National Institutes of Health. ClinicalTrials.gov identifier: NCT05433350. 2026. https://clinicaltrials.gov/study/NCT05433350. Accessed 16 Jun 2026.

US National Institutes of Health. ClinicalTrials.gov identifier: NCT06356974. 2026. https://clinicaltrials.gov/study/NCT06356974. Accessed 16 Jun 2026.

Nicco E, Lejon V, Mwamba Miaka E, et al. The STROGHAT study protocol: an intervention study to evaluate safety, effectiveness and feasibility of treating gambiense HAT seropositive subjects with acoziborole. Open Res Eur. 2025;5(23):1–22.

Google Scholar